Squarepoint’s Burning Rock Biotech BNR Stock Holding History

Squarepoint’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,103	Closed	-$122K	–	3197
2022 Q3	$122K	Buy	+5,103	New	+$165K	﹤0.01%	2770

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Squarepoint's BNR Position: Q4 2022 in Review

Squarepoint sold out of Burning Rock Biotech (BNR) in Q4 2022, closing a stake of 5,103 shares — an estimated $122K sold.

Squarepoint first reported a position in BNR in Q3 2022 and held it in 1 quarter. The position peaked at $122K in Q3 2022. 42 funds tracked by Wall St. Rank hold BNR as of Q4 2022.

Squarepoint reported no remaining Burning Rock Biotech position as of Q4 2022 after selling out during the quarter.
Squarepoint sold 5,103 Burning Rock Biotech shares in Q4 2022, an estimated $122K.
Squarepoint first reported a position in Burning Rock Biotech in Q3 2022 and held it in 1 quarter.
Squarepoint's Burning Rock Biotech position peaked at $122K in Q3 2022.
42 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2022.

Based on Squarepoint's 13F filing for Q4 2022, filed 14 Feb 2023.